Harmonizing Clinical Practices: Strategies for Rapid Diagnosis and Acute Management of Acquired TTP

Release Date: August 24, 2021
Expiration Date: August 24, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts with experience providing care to patients with acquired, immune-mediated thrombotic thrombocytopenic purpura (TTP). In this educational program, these experts discuss the pathophysiology and clinical picture of the disorder, share insights on the application of consensus guidelines, its management, and provide practical advice for handling challenging cases.

This educational activity is an archive of the live virtual symposium held on July 19, 2021

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Sanofi Genzyme.
 

Instructions for This Activity and Receiving Credit Complete the activity (including pre- and post-activity assessments). Answer the evaluation questions. Request credit using the drop-down menu. You may immediately download your certificate.

Target Audience

This activity is intended for hematologists and hematologist/oncologists who treat patients with aTTP. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals interested in the management of patients with aTTP are also invited to participate.

Learning Objectives

At the conclusion of this activity, you should be better prepared to:

• Review diagnostic challenges that are specific to acquired, immune-mediated TTP
• Apply disease-specific tests used to diagnose acquired, immune-mediated TTP based on clinical manifestations
• Analyze clinical trial data of approved and investigational therapies for the treatment of acquired, immune-mediated TTP
• Integrate clinical guideline recommendations into the management of acquired, immune-mediated TTP

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Disclosures: Grant research support: Sanofi Genzyme, Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals Inc.; Consultant: Sanofi Genzyme, Takeda Pharmaceutical Company Limited; Advisory board: Alexion Pharmaceuticals

Disclosures: Shareholder: Takeda Pharmaceutical Company Limited, Sanofi Genzyme, Octapharma AG, Novartis; Grant research support: Shire plc, Novartis; Consultant: Takeda Pharmaceutical Company Limited, Sanofi Genzyme, Octapharma USA, Novartis; Advisory board: Alexion Pharmaceuticals, Takeda Pharmaceutical Company Limited; Speaker or a member of a speakers bureau for: Alexion Pharmaceuticals; Novartis; Sanofi Genzyme; Takeda Pharmaceutical Company Limited

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.